When do biologic drug patents expire and when will biosimilars launch?

US Patent 10,143,752 Landscape: What Claims Protect (and What Generic/Biosimilar Risks Remain) for 300 mg Vedolizumab Every 8 Weeks in Ulcerative Colitis

Executive summary

US 10,143,752 is drafted around a specific dosing-and-response method claim for ulcerative colitis (UC): 300 mg vedolizumab IV every 8 weeks (and an equivalent method using an antibody defined by particular heavy/light variable region sequence windows), with the biological endpoint defined as mucosal healing = endoscopic subscore ≤1 and clinical remission maintained.
The enforceable core is narrow in practice: it is not a “treatment for UC with anti-α4β7” claim in the abstract, but a method tied to (i) dose, (ii) route/timing, and (iii) endpoint definition plus additional limitations (TNF-ex failure; infusion ~30 minutes; specific sequence windows).
For biosimilar or generic method-entry risk, the litigation/entry problem is less about “can the product be made” and more about whether the accused product and prescribing behavior meet every claim element, especially the dose schedule and endoscopic endpoint.

1. What is US Patent 10,143,752 actually claiming? (method scope vs “product” scope)

Fast answer: The patent claims methods of use for UC that require IV administration of 300 mg anti-α4β7 on an every-8-weeks schedule, with mucosal healing defined by an endoscopic subscore ≤1, plus additional narrowing limitations in dependent claims.

Independent claim (Claim 1): the claim spine

Claim 1 requires all of the following:

Patient population: human with moderately to severely active ulcerative colitis.
Therapy: intravenously administer 300 mg of an antibody binding specifically to human α4β7 integrin.
Dose cadence: every eight weeks.
Antibody identity (sequence-constrained): heavy chain variable region amino acids 20–140 of SEQ ID NO:2 and light chain variable region amino acids 20–131 of SEQ ID NO:4.
Clinical outcome: the method includes that mucosal healing is achieved and clinical remission is maintained.
Endpoint definition: mucosal healing is defined as endoscopic subscore ≤1.

Practical implication: A party arguing non-infringement can focus on any single element, especially:

different dosing (non-300 mg or different interval),
different dosing route (SC or IV not matching claim),
different antibody sequence outside the claimed windows,
different endpoint used for “mucosal healing” (or different clinical definition in study/labeling),
different patient characterization (though dependent claim 4 narrows TNF-ex failures).

Dependent claims (Claims 2–4): further tightening

Claim 2: further narrows chain definitions:
- heavy chain includes amino acids 20–470 of SEQ ID NO:2
- light chain includes amino acids 20–238 of SEQ ID NO:4
Claim 3: requires infusion administration over about 30 minutes.
Claim 4: patient must have lack of adequate response to, lost response to, or intolerance to a TNFα antagonist.

Claim 5: explicit “vedolizumab 300 mg every 8 weeks” with the same mucosal endpoint

Claim 5 is a parallel formulation of Claim 1, but it names vedolizumab directly and retains:

300 mg IV every 8 weeks
UC with mucosal healing achieved and clinical remission maintained
mucosal healing defined as endoscopic subscore ≤1

Key reading: Claim 5 is less helpful for generic product design-around than Claim 1’s sequence-constraint, but it narrows fewer variables because the antibody is named.

2. What patents protect vedolizumab mucosal healing on an endoscopic subscore ≤1 at 300 mg IV q8w in US?

Fast answer: US 10,143,752 sits in the “second-layer” category: method-of-use protection tying anti-α4β7 therapy to a defined endoscopic healing endpoint under a specific regimen (300 mg IV q8w). It is not the primary composition-of-matter layer that typically governs core product exclusivity.

How this claim class usually interacts with the broader vedolizumab estate

For a full freedom-to-operate (FTO) assessment, the relevant layers are generally:

Composition-of-matter patents on the antibody sequences and constructs (often earlier-expiring).
Formulation/manufacturing patents (vehicle, stability, concentration).
Method-of-use patents tied to patient subsets, endpoints, and dosing regimens (later-expiring or still active depending on priority chain).
Regulatory exclusivities (biologic exclusivity; pediatric; etc.), which do not substitute for patent infringement risk on method claims.

Where US 10,143,752 fits: it is specifically anchored to the endpoint “endoscopic subscore of 1 or less” and regimen 300 mg IV every 8 weeks, which aligns closely with the therapeutic development focus on endoscopic outcomes in UC.

3. When does US 10,143,752 lose exclusivity? What is the expiration risk timeline?

Fast answer: A claim like this typically tracks the utility patent expiration plus any adjustment, not the biologic exclusivity clock. Without the patent’s expiration/adjustment data in the prompt, the analysis cannot produce exact dates.

Operational impact: For business planning, this kind of method claim is usually evaluated on:

the earliest expiration of the specific patent,
whether there are terminal disclaimers affecting parts of the estate,
whether there are interfering continuations or divisional relationships,
and whether any PTA has been granted.

Because the prompt does not include the patent’s filing date, priority date, or expiration/adjustment data, this response cannot state exact calendar dates.

4. What is the Orange Book status of US 10,143,752? Does it list?

Fast answer: Orange Book listings are for small molecules; vedolizumab is a biologic, so it typically does not appear in the Orange Book in the same way as standard drug products. For biologics, relevant patent listings are usually found in the BPCIA patent listing process tied to the biologics license application and in the FDA biologics patent information framework, not the Orange Book.

Critical point for litigation posture: method patents like this may still be part of a biologics patent listing bundle, but they are not an “Orange Book drug patent” in the classic Orange Book sense.

5. How strong is the patent estate for mucosal healing methods in UC using vedolizumab (and what makes this claim vulnerable)?

Fast answer: Strength is driven by (i) the tight regimen constraints and (ii) the endpoint definition. Those same constraints create vulnerability: an accused party can avoid infringement by changing one required element, or by showing the method is not practiced as claimed.

Strength factors (pro-assertion)

Specific regimen: 300 mg IV q8w is more particular than “anti-α4β7 every so often.”
Specific endpoint definition: requiring endoscopic subscore ≤1 narrows the “mucosal healing” notion to a quantifiable threshold.
Antibody identity constraints in Claim 1: the variable region window definitions can help distinguish non-vedolizumab antibodies.

Vulnerability factors (anti-infringement and design-around)

Endpoint tethering: many real-world treatment objectives use broader or differently defined remission endpoints. If the accused practice does not meet the “endoscopic subscore ≤1” definition, a method-of-use claim can be attacked on non-practice of an element.
Patient subgroup dependence: if litigation focuses on Claim 4 (TNF antagonist failure), a defense can argue that the method is not targeted to that subgroup.
Infusion time window: Claim 3 requires infusion over “about 30 minutes.” If a product’s label or practice uses substantially different infusion duration, infringement can be contested.
Biosimilar interchangeability and naming: even if biosimilars are highly similar, infringement turns on whether the antibody meets the claimed variable-region sequence constraints (for Claim 1) and whether physicians/companies practice the claimed regimen and endpoint.

6. What generic entry risks exist for this method claim (and do Paragraph IV filings apply)?

Fast answer: Paragraph IV is for ANDA small-molecule generics. A vedolizumab biosimilar route uses the BPCIA framework, not Paragraph IV.

Real entry risk for biologics against method patents

For biologic competition, risk typically comes from:

Biosimilar/biologic license application patent challenges under the BPCIA,
potential injunctive relief on infringement of method-of-use claims,
settlement structures that delay launch or carve out prescribing behavior.

Method claims are often the focal point because they control clinical practice rather than only the product itself.

7. How does this patent compare with vedolizumab’s typical prior art and clinical trial endpoint definitions?

Fast answer: The endoscopic subscore threshold of ≤1 is consistent with common UC endoscopic scoring frameworks used in clinical studies of biologic therapies. The more that real-world and study endpoints align, the harder it is to argue the endpoint is not being “achieved” when the regimen is used.

Claim construction exposure

In method patents, disputes often turn on:

what the “endoscopic subscore” refers to (the scoring system),
measurement timing (post-induction evaluation timepoint vs any subsequent measurement),
whether “mucosal healing is achieved” requires documentation in the accused context (evidence problem),
and whether “clinical remission maintained” requires a defined remission endpoint (not fully specified in the prompt).

Because the prompt does not include the patent’s full specification language on remission definition, this cannot be fully mapped to exact infringement standards.

8. What formulation or manufacturing patents could coexist and block “around-the-method” strategies?

Fast answer: A method-of-use patent does not protect formulation. A would-be entrant can switch:

delivery system,
infusion time,
induction regimen,
monitoring endpoints.

But those changes do not neutralize formulation/manufacturing or composition claims that may exist in the broader vedolizumab estate.

Critical interaction: Even if a competitor changes infusion rate or endpoint definition, it must still be free to market the biosimilar product under any remaining product and manufacturing patents.

9. What patent litigation affects US 10,143,752 and related UC anti-α4β7 method claims?

Fast answer: The prompt does not provide litigation captions, dockets, or settlement terms tied to US 10,143,752. Without those records, this response cannot accurately identify active cases, outcomes, or case-specific claim construction.

10. How many jurisdictions and parties are impacted by this method claim in the US?

Fast answer: Method claims in the US require infringement by “use” in the jurisdiction. But the prompt provides no BPCIA listings, no accused products, and no party list, so this response cannot quantify impacted parties or map jurisdictional coverage beyond the US.

11. Claim-by-claim infringement mapping: what an accused product/practice must do to infringe?

Claim 1 checklist

To infringe Claim 1, an accused method must practice all elements:

Element	Requirement in US 10,143,752 Claim 1	Common ways to attempt non-infringement
Indication	Moderately to severely active UC	Different indication population; different trial/labeling scope
Active antibody	Anti-human α4β7 integrin	Different target or binding profile
Dose	300 mg	Different dose strength; different per-administration amount
Route	IV	Different route (SC)
Frequency	Every 8 weeks	Different interval
Antibody identity	Heavy var 20–140 of SEQ ID NO:2; light var 20–131 of SEQ ID NO:4	Different sequence in those windows; analytical comparison
Mucosal healing definition	Endoscopic subscore ≤1	Use different endoscopic definition or show endpoint not met in practice
Clinical outcome	Mucosal healing achieved and remission maintained	Dispute endpoint evidence and timing

Claim 2 additional constraints

A defense that defeats Claim 1’s variable windows can also defeat Claim 2, but even if sequences match the Claim 1 windows, Claim 2 expands the sequence span requiring additional identity.

Claim 3 administration duration

This is a practical infringement and evidence lever:

if infusion is not “about 30 minutes” for the accused regimen, Claim 3 is vulnerable.

Claim 4 TNFα antagonist failure subgroup

This claim is only implicated when the method is used for a patient with:

inadequate response,
lost response, or
intolerance to TNFα antagonist therapy.

If clinical practice or trial populations exclude that subgroup, Claim 4 is harder to assert.

Claim 5 direct vedolizumab naming

Claim 5 reduces ambiguity about antibody identity:

the key defenses shift back to dose schedule, route, and endpoint.

12. Commercial exposure: what revenue scenario does this method protection support?

Fast answer: A dosing-and-endpoint method claim is economically valuable when it can:

block biosimilar substitution for a labeled regimen,
support settlement-based delay,
or shape prescribing behavior.

But the prompt provides no sales, market share, or forecast numbers, so this response cannot quantify revenue at risk.

Key Takeaways

US 10,143,752 protects a UC mucosal healing method with vedolizumab/anti-α4β7 constrained to 300 mg IV every 8 weeks and a defined healing endpoint endoscopic subscore ≤1.
The claim is narrow enough that non-infringement arguments often come from changing regimen elements (dose, interval, infusion duration) or showing the endoscopic endpoint is not met under the accused method.
Claim 1’s variable-region sequence windows add an antibody-identity constraint; Claim 5 simplifies antibody identity by naming vedolizumab.
Entry-risk is framed under BPCIA biosimilar/patent listing mechanics, not Paragraph IV.

FAQs

Can a biosimilar avoid infringement of US 10,143,752 by using a different infusion time than ~30 minutes?
Does US 10,143,752 require the endoscopic subscore to be documented in the accused clinical practice, or is prospective dosing enough?
If a TNFα antagonist-naïve UC patient is treated with vedolizumab 300 mg IV q8w, does Claim 4 still apply?
How do variable-region sequence window claims (Claim 1/2) affect an analytical comparability strategy for biosimilars?
If a clinician prescribes vedolizumab 300 mg IV every 7 or 9 weeks, which claim elements are immediately broken?

References

U.S. Patent 10,143,752. United States Patent and Trademark Office (USPTO). (Claims excerpt provided in prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	May 20, 2014	10,143,752	2036-07-20
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	Injection	761133	September 27, 2023	10,143,752	2036-07-20
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133	September 27, 2023	10,143,752	2036-07-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,143,752

Summary for Patent: 10,143,752